Vaccine trials are critical in developing new, safe and effective tools to prevent infectious diseases. Peripheral Blood Mononuclear Cell (PBMC) isolation plays a significant role in the study and development vaccines by providing a sample of peripheral blood into two distinct populations: mononuclear cells and other cells. 



QPS has two fully equipped PBMC laboratories with experienced technicians who can perform optimal separation of lymphocytes and peripheral mononuclear cells. PBMC services can be provided as a stand-alone service, or as part of a full-service clinical trial.

Our state-of-the-art laboratories include:

Leukapheresis, focuses on collecting white blood cells (WBCs), with the remaining blood components returned to the donor. Research use only (RUO) leukopaks can be utilized to develop therapeutics in the fields of transplant therapy, cell therapy, and regenerative medicines to treat various cancers, immune disease, metabolic diseases, neurodegenerative disease, and a wide spectrum of other diseases. 

Mobilized Leukopaks are apheresis products containing CD34+ hematopoietic stem and progenitor cells (HSPCs) from healthy donors' peripheral blood. "Mobilized" leukopaks are created by stimulating the release of HSPCs from the bone marrow into the bloodstream using hematopoietic growth factors.